Onconetix (ONCO) Total Liabilities (2021 - 2026)
Onconetix (ONCO) posted quarterly Total Liabilities of $3.1 million for Q1 2026, down 78.37% year-over-year from $14.3 million in Q1 2025, and down 66.33% quarter-over-quarter from $9.2 million in Q4 2025.
Onconetix (ONCO) Total Liabilities (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Total Liabilities for 6 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 78.37% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 78.37% YoY), while the FY2025 annual figure was $9.2 million, down 50.67% from the prior year.
- Total Liabilities retreated to $3.1 million in Q1 2026 per ONCO's latest filing, from $9.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $25.3 million in Q1 2024 and bottomed at $860204.0 in Q3 2022.
- Historically, Total Liabilities has averaged $13.9 million across 5 years, with a median of $16.3 million in 2025.
- Annual changes were most pronounced in 2023 — Total Liabilities plunged 85.47% — and 2024, when it surged 800.56%.
- Onconetix's Total Liabilities stood at $3.9 million in 2022, then soared by 457.75% to $21.9 million in 2023, then dropped by 15.11% to $18.6 million in 2024, then tumbled by 50.67% to $9.2 million in 2025, then sank by 66.33% to $3.1 million in 2026.
- Business Quant data shows ONCO's Total Liabilities at $3.1 million in Q1 2026, $9.2 million in Q4 2025, and $16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 2.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.96 Mn |
| Mar 31, 2026 | 3.08 Mn |
| Dec 31, 2025 | 9.16 Mn |
| Sep 30, 2025 | 16.30 Mn |
| Jun 30, 2025 | 12.77 Mn |
| Mar 31, 2025 | 14.26 Mn |
| Dec 31, 2024 | 18.57 Mn |
| Sep 30, 2024 | 20.90 Mn |
| Jun 30, 2024 | 23.96 Mn |
| Mar 31, 2024 | 25.29 Mn |
| Dec 31, 2023 | 21.88 Mn |
| Sep 30, 2023 | 2.61 Mn |
| Jun 30, 2023 | 16.67 Mn |
| Mar 31, 2023 | 2.81 Mn |
| Dec 31, 2022 | 3.92 Mn |
| Sep 30, 2022 | 860,204.00 |
| Jun 30, 2022 | 23.63 Mn |
| Mar 31, 2022 | 19.34 Mn |
| Dec 31, 2021 | 1.64 Mn |